TY - JOUR
T1 - Aβ40 reduces p-glycoprotein at the blood–brain barrier through the ubiquitin–proteasome pathway
AU - Hartz, Anika M.S.
AU - Zhong, Yu
AU - Wolf, Andrea
AU - LeVine, Harry
AU - Miller, David
AU - Bauer, Björn
N1 - Publisher Copyright:
© 2016 the authors.
PY - 2016/2/10
Y1 - 2016/2/10
N2 - Failure to clear amyloid-β (Aβ) from the brain is in part responsible for Aβ brain accumulation in Alzheimer’s disease (AD). A critical protein for clearing Aβ across the blood–brain barrier is the efflux transporter P-glycoprotein (P-gp) in the luminal plasma membrane of the brain capillary endothelium. P-gp is reduced at the blood–brain barrier in AD, which has been shown to be associated with Aβ brain accumulation. However, the mechanism responsible for P-gp reduction in AD is not well understood. Here we focused on identifying critical mechanistic steps involved in reducing P-gp in AD. We exposed isolated rat brain capillaries to 100 nM Aβ40, Aβ40, aggregated Aβ40, and Aβ42. We observed that only Aβ40 triggered reduction of P-gp protein expression and transport activity levels; this occurred in a dose- and time-dependent manner. To identify the steps involved in Aβ-mediated P-gp reduction, we inhibited protein ubiquitination, protein trafficking, and the ubiquitin–proteasome system, and monitored P-gp protein expression, transport activity, and P-gpubiquitin levels. Thus, exposing brain capillaries to Aβ40 triggers ubiquitination, internalization, and proteasomal degradation of P-gp. These findingsmayprovide potential therapeutic targets within the blood–brain barrier to limit P-gp degradation in AD and improve Aβ brain clearance.
AB - Failure to clear amyloid-β (Aβ) from the brain is in part responsible for Aβ brain accumulation in Alzheimer’s disease (AD). A critical protein for clearing Aβ across the blood–brain barrier is the efflux transporter P-glycoprotein (P-gp) in the luminal plasma membrane of the brain capillary endothelium. P-gp is reduced at the blood–brain barrier in AD, which has been shown to be associated with Aβ brain accumulation. However, the mechanism responsible for P-gp reduction in AD is not well understood. Here we focused on identifying critical mechanistic steps involved in reducing P-gp in AD. We exposed isolated rat brain capillaries to 100 nM Aβ40, Aβ40, aggregated Aβ40, and Aβ42. We observed that only Aβ40 triggered reduction of P-gp protein expression and transport activity levels; this occurred in a dose- and time-dependent manner. To identify the steps involved in Aβ-mediated P-gp reduction, we inhibited protein ubiquitination, protein trafficking, and the ubiquitin–proteasome system, and monitored P-gp protein expression, transport activity, and P-gpubiquitin levels. Thus, exposing brain capillaries to Aβ40 triggers ubiquitination, internalization, and proteasomal degradation of P-gp. These findingsmayprovide potential therapeutic targets within the blood–brain barrier to limit P-gp degradation in AD and improve Aβ brain clearance.
KW - Alzheimer’s disease
KW - Blood–brain barrier
KW - P-glycoprotein
KW - Transporter
KW - Ubiquitin–proteasome system
UR - http://www.scopus.com/inward/record.url?scp=84958817297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958817297&partnerID=8YFLogxK
U2 - 10.1523/JNEUROSCI.0350-15.2016
DO - 10.1523/JNEUROSCI.0350-15.2016
M3 - Article
C2 - 26865616
AN - SCOPUS:84958817297
SN - 0270-6474
VL - 36
SP - 1930
EP - 1941
JO - Journal of Neuroscience
JF - Journal of Neuroscience
IS - 6
ER -